Reference values for specific parameters of hemostasis determined with the automated analyzer

The article defines reference values for von Willebrand factor activity, von Willebrand factor ristocetin cofactor activity, von Willebrand factor antigen, Factor VIII Chromogenic assay activity, d‑dimer and Plasminogen activator inhibitor activity according to existing standards on the automatic coagulometer Sysmex CS‑2000i.

The aim of the study: to determine reference values for specific parameters of the hemostasis, which may vary depending on the type of analyzer and utilized reagents.

Materials and methods. After receiving informed voluntary consent from donors for medical survey and blood and (or) its components donation, blood samples were obtained from 100 donors of blood and (or) its components of both sexes: 51 males (51%) и 49 females (49%). We established reference values with the Sysmex CS‑2000i (Sysmex Corporation, Japan) hemostasis analyzer and reagents from Siemens (Healthcare GmbH, Germany).

Results. Reference values obtained for von Willebrand factor activity (46,65–181,45%), von Willebrand factor ristocetin cofactor activity (16,77– 164,37%), von Willebrand factor antigen (52,11% – 169,27%), Factor VIII chromogenic assay (45,08–158,35%), d‑dimer (17,69–368,13 mcg/l) and Plasminogen activator inhibitor activity (–2,54–4,48 E/ml), were compared with the literature data and the data presented in the instructions for the reagents used. The results obtained for von Willebrand factor antigen (52,11–169,27%) and d‑dimer (17,69–368,13 mcg/l) are comparable to the available data. There are no data on other studied parameters of hemostasis for the Sysmex CS‑2000i analyzer and the reagents used in the work. The obtained reference intervals are generally consistent with the manufacturer’s recommendations.

Conclusions. Reference values vary significantly depending on the analytical systems and reagent kits used, which confirms the need for local derivation or validation of reference intervals for each specific analytical system and in each laboratory.

1. Lillicrap D. Von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 2013; 122 (23): 3735–3740. DOI: 10.1182/blood-2013-06-498303

2. Likhacheva E.A., Polyanskaya T. Yu., Zorenko V. Yu. International experience in the diagnosis and treatment of von Willebrand disease. Hematology and Transfusiology. 2013; 58 (4): 45–9. (In Russ.).

3. Lippi G., Favaloro E.J., Franchini M. Dangers in the practice of defensive medicine in hemostasis testing for investigation of bleeding or thrombosis: part I – routine coagulation testing. Review Semin Thromb Hemost. 2014; 40 (7): 812–24. DOI: 10.1055/s-0034-1394108

4. Yildiz S.Y., Kuru P., Oner E.T., Agirbasil M. Functional Stability of Plasminogen Activator Inhibitor 1. The Scientific World Journal. 2014; 11 pages. DOI: 10.1155/2014/858293

5. Andreeva T. A., Zharkov P. A., Zozulya N. I., Zorenko V. Yu., Konstantinova V. N., Lebedev V.V., Mamaev A.N., Markova I.V., Petrov V. Yu., Polyanskaya T. Yu., Schiller E.E. Management of patients with hemophilia a on emicizumab prophylactic treatment: recommendation from russian experts. Hematology and transfusiology. 2022; 67 (2): 267–280. (In Russ.). DOI: 10.35754/0234-5730-2022-67-2-267-280

6. Yee A., Kretz C.A. Von Willebrand factor: Form for function. Semin Thromb Hemost. 2014; 40 (1): 17–27. DOI: 10.1055/s-0033-1363155

7. Clinical guidelines for the diagnosis and treatment of Willebrand’s disease. Approved at the IV Congress of Hematologists of Russia; 2018. (In Russ.).

8. Lethagen S. von Willebrand’s disease: pathogenesis and clinical aspects. Crit Rev Oncol Hematol. 1993; 15: 1–11.

9. Goodeve A.C. The genetic bases of von Willebrand disease. Blood Rev. 2010; 24 (3): 123–34. DOI: 10.1016/j.blre.2010.03.003

10. Bharati K.P., Prashanth U.R Von Willebrand disease: an overview. Indian J Pharm Sci. 2011; 73 (1): 7–16. DOI: 10.4103/0250-474X.89751

11. Michiels J.J., Gadisseur A., Budde U., Berneman Z., Planken M., Schroyens W., Velde A., Vliet H. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Semin Thromb Hemost. 2005; 31 (5): 577–601. DOI: 10.1055/s-2005-922230

12. Collins P., Budde U., Rand H., Federici A. B., Ressler C. M. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia. 2008; 14 (Suppl. 3): 49–55.

13. Voigtländer M., Langer F. Cancer associated coagulation disorders. Dermatologie (Heidelb). 2022; 73 (10): 809–819. DOI: 10.1007/s00105-022-05056-8

14. Khadadah F., Rupani N, Scott J., Trinkaus M., Teitel J., Sholzberg M. Lymphoma associated acquired von Willebrand syndrome responsive to splenectomy: A case report. E.J. Haem. 2022; 31 (3): 996–999. DOI: 10.1002/jha2.486

15. Mondal S., Hollander K.N., Ibekwe S.O., Williams B., Tanaka K. Heyde Syndrome–Pathophysiology and Perioperative Implications. Journal of Cardiothoracic and Vascular Anesthesia. 2021; 35 (11): 3331–9.

16. Hollestelle M.J, Loots C.M, Squizzato A., Renne T., Bouma B.J, de Groot P.G., et al. Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients. J Thromb Haemost. 2011; 9(5): 953–8. DOI: 10.1111/j.1538-7836.2011.04247.x

17. Favaloro E.J., Pasalic A., Curnow J. Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology. 2016; 48(4): 303–18. DOI: 10.1016/j.pathol.2016.03.001

18. Novembrino С., Anzoletti M.B., Mancuso M.E., Shinohara S., lPeyvandi F. Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A. Haemophilia. 2018; 2019; 25: 521–526. DOI: 10.1111/hae.13746

19. Jenkins V., Bowyer A., Burgess C., Gray E., Kitchen S., Murphy P., Platton S., Riddell A., Chowdary P., Lester W. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors’ Organisation guideline. Haemophilia. 2020; 26: 151–155. DOI: 10.1111/hae.13903

20. Makarova P.M., Galstyan G.M. Protocol for the treatment of septic shock. In: Diagnostic algorithms and treatment protocols for diseases of the blood system. In 2 v. Moscow, 2018. 1191–1201. (In Russ.). ID: 32828517

21. Pène F., Percheron S., Lemiale V., Viallon V., Claessens Y. E., Marqué S., Charpentier J., Angus D.C., Cariou A., Chiche J. D., Mira J. P. Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med. 2008; 36 (3): 690–6. DOI: 10.1097/CCM.0B013E318165314B

22. Zuber B., Tran T. C., Aegerter P., Grimaldi D., Charpentier J., Guidet B., Mira J. P, Pène F., CUB Réa Network. Impact of case volume on survival of septic shock in patients with malignancies. Crit Care Med. 2012; 40 (1): 55–62. DOI: 10.1097/CCM.0b013e31822d74ba

23. Avnery O., Martin M., Bura Riviere A., Barillari, Mazzolai L., Mahé I., Marchena P.J., Verhamme P., Monreal M., Ellis M.H. D dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. J Intern Med. 2020; 287 (1): 32–41. DOI: 10.1111/joim.12969

24. Bjøri E., Johnsen H.S., Hansen J B., Braekkan S.K. D dimer at venous thrombosis diagnosis is associated with risk of recurrence. J Thromb Haemost. 2017; 15 (5):917–924. DOI: 10.1111/jth.13648

25. Lippi G., Franchini M., Targher G., Favaloro E.G. Help me, Doctor! My D dimer is raised. Ann Med. 2008; 40 (8): 594–605. doi: 10.1080/07853890802161015.

26. Gao Y., Li T., Han M., Xiuyong Li, Wu D., Xu Y., Zhu Y., Yan Liu, Wang X., Wang L. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID 19. J Med Virol. 2020; 92 (7): 791 7966. doi: 10.1002/jmv.25770

27. Yakovleva E.V., Dimitrieva O.S., Zozulya N.I. Coronavirus infection in patients with hereditary coagulopathies. In the collection: The Russian Forum on Thrombosis and Hemostasis together with the 10th (anniversary) Conference on Clinical Hemostasiology and Hemorheology. Collection of materials. National Association for Thrombosis and Hemostasis. 2020; 131. (In Russ.).

28. Galstyan G.M. Coagulopathy in Covid 19. Pulmonology. 2020; 30 (5): 645–657. (In Russ.). DOI: 10.18093/0869-0189-2020-30-5-645-657

29. Binder B.R., Christ G., Gruber F., Grubic N., Hufnagl P., Krebs M., Mihaly J., Prager G.W. “Plasminogen activator inhibitor 1: physiological and pathophysiological roles”. News in Physiological Sciences. 2002; 17: 56–61. PMID11909993.

30. Vaughan D.E. PAI 1 and atherothrombosis. Journal of Thrombosis and Haemostasis, 2005; 3: 1879–83. DOI: 10.1111/j.1538-7836.2005.01420.x

31. Mutch N.J., Thomas L., Moore N.R., Lisiak K.M., Booth N.A. TAFIa, PAI 1 and α2 antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. Journal of Thrombosis and Haemostasis, 2007; 5: 812–7. DOI: 10.1111/j.1538-7836.2007.02430.x

32. Cesaro S., Mauro M, Sattin G, Sartori M.T, Saggiorato G, Paratella A., Tridello G., Bisogno G. PAI 1 and protein C as early markers of veno occlusive disease in patients treated for Wilms tumor. Pediatr Blood Cancer. 2019; 66 (7): e27695. DOI: 10.1002/pbc.27695

33. Argren A., Wiman B., Stiller V., Lindmarker P., Sten Linder M., Carlsson A., Holmstrom, Odeberg M.J., Schulman S. Evaluation of low PAI 1 activity as a risk factor for hemorrhagic diathesis. Journal of Thrombosis and Haemoctasis. 2005; 4: 201–8. DOI: 10.1111/j.1538-7836.2005.01709.x

34. Kahl B.S., Schwartz B.S., Mosher D.F. Profound imbalance of pro fibrinolytic and anti fibrinolytic factors (tissue plasminogen activator and plasminogen activator inhibitor type 1) and severe bleeding diathesis in a patient with cirrhosis: correction by liver transplantation. Blood Coagul Fibrinolysis. 2003; 14: 741–4. DOI: 10.1097/00001721-200312000-00008

35. GOST R53022 3 2008. Laboratory and clinical technologies. Requirements for the quality of laboratory tests. Rules for evaluating the clinical effectiveness of laboratory tests.– М., 2008. (In Russ.).

36. Clinical and Laboratory Standards Institute (CLSI). Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory, Approved Guideline. 3rd ed. CLSI document. 2008: 28–33.

37. Block B.J., Dolan C.T., Miller G.C., Fitter W.F., Harstell B.D., Crowson A.N., Sheehan W.W., Williams J.D. The data warehouse as a foundation for population based reference intervals. Am.J. Clin. Pathol. 2003; 120: 662–670. DOI: 10.1309/W8J8-5AG4-WDG6-JGJ9

38. Jones G.R.D, Berker A., Tate J., Lim C.F., Robertson K. The case for common reference intervals. Clin. Biochem. Rev. 2004; 25: 99–104. PMCID: PMC1904413

39. Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. 3rd еd. Wayne, PA: Clinical and Laboratory Standards Institute, 2008; 28(3). Document C28 A3.

40. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Official J. Eur. Commun. 1998; L331: 1–37.

41. Qari M.H. High throughput coagulation analyzers review. Comb Chem High hroughput Screen. 2005; 8 (4): 353–60. DOI: 10.2174/1386207054020796

42. Malati T. Whether western normative laboratory values used for clinical diagnosis are applicable to Indian population? An overview on reference interval. Indian J Clin Biochem. 2009; 24(2): 111–22. DOI: 10.1007/s12291-009-0022-1

43. Horn P.S, Feng L., Li Y., Pesce A.J. Effect of outliers and nonhealthy individuals on reference interval estimation. Clinical Chemistry. 2001; 47: 2137–45. PMID: 11719478

44. Bronić A, Margetić S, Coen D., Milić M., Kreši B, Biljak V.R., Krleža J.L. Reporting of activated partial thromboplastin time (aPTT): Could we achieve better comparability of the results? Biochem. Med. 2021; 31(2): 020708. DOI: 10.11613/BM.2021.020708

45. Martin Toutain I, Jobic L, Mancic T., Ankri A. Evaluation of the automated coagulation analyzer Sysmex(®) CS 2100i (Siemens). Ann Biol Clin. 2011; 69(6): 699–704. DOI: 10.1684/abc.2011.0624

46. Martin Toutain I., Jobic L., Mancic T., Brissard A., Ankri A. Evaluation of the automated coagulation analyser Sysmex(®) CS 5100 (Siemens). Ann Biol Clin. 2015; 73(4): 413–9. DOI: 10.1684/abc.2015.1054

47. Appel I.M., Grimminck B., Geerts J., Stigter R., Cnossen M.H., Beishuizen A. Age dependency of coagulation parameters during childhood and puberty. J Thromb Haemost. 2012;10(11): 2254–63. DOI: 10.1111/j.1538-7836.2012.04905.x

48. Lethagen S., Hillarp A., Ekholm C., Mattson E., Halldén C., Friberg B. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes. Thromb Haemost. 2008; 99 (6): 1013–8. DOI: 10.1160/TH07-06-0419

49. Favaloro E.J., Soltani S., McDonald J., Grezchnik E., Easton L, Favaloro J.W.C. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis. Am J Clin Pathol. 2006; 125 (5): 796. PMID: 16416741

50. James P. D., Connell N. T., Ameer B, Paola J.D., Eikenboom J., Giraud N., Haberichter S., Jacobs Pratt V., Konkle B., McLintock C., McRae S., Montgomery R.R., O’Donnell J.S., Scappe N., Sidonio R., Flood V.H., Husainat N., Mohamad A.K., Mustafa R.A. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021; 5(1): 280–300 DOI: 10.1182/bloodadvances.2020003265

51. Kitchen S., Jennings I., Woods T. A., Kitchen D. P., Walker I. D., Preston F. E. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemos.t 2006; 32: 492–8. DOI: 10.1055/s-2006-947863

52. Chandler W.L., Peerschke E.I., Castellone D.D., Meijer P. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Path. 2011; 135: 862–9. DOI: 10.1309/AJCPH5JK4ONENPAE

53. Hayes T E, Brandt J.T., Chandler W.L., Eby C.S., Kottke Marchant K., Krishnan J., Lefkowitz J.B., Olson J.D., Rund C.R., Van Cott E.M., Cunningham M.T. External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program. Semin Thromb Hemost 2006; 32: 499–504. DOI: 10.1055/s-2006-947864

54. Sadler J.E., Budde U., Eikenboom J.C., Favaloro E.J., Hill F.G., Holmberg L., et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006; 4: 2103–14. DOI: 10.1111/j.1538-7836.2006.02146.x

55. Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ. Laboratory diagnosis and molecular classification of von Willebrand disease. Acta Haematol. 2009; 121: 71–84. DOI: 10.1159/000214846

56. Flood V.H., Gill J.C., Morateck P.A., Christopherson P.A., Friedman K.D., Haberichter S.L., et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010; 116: 280–6. DOI: 10.1182/blood-2009-10-249102

57. Lawrie A.S., Stufano F., Canciani M.T., Mackie I.J., Machin S.J., Peyvandi F.A. comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia. 2013; 19: 338–42. DOI: 10.1111/hae.12064

58. Gorgidze L. A., Mamleeva S. Yu., Pimenov M. S., Smirnova A. V., Bulgakov A. V., Galstyan G.M. Reference values of activated partial thromboplastin time, quicks value, INR, thrombin time, fibrinogen, antithrombin and II, V, VII, VIII, IX, X, XI and XII coagulation factors determined with automated Sysmex CS 2000i analyzer. The Medical Alphabet. 2023; (4): 13–17. (In Russ.). DOI: 10.33667/2078-5631-2023-4-13-17

59. Peyvandi F., Oldemburg J., Friedman KD. A critical appraisal of one stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016; 14: 248–2617. DOI: 10.1111/jth.13215

60. Potgieter J.J., Damgaard M., Hillarp A. One stage vs. chromogenic assays in haemophilia A. Eur J Haematol. 2015; 94: 38–44. DOI: 10.1111/ejh.12500

61. Giardina EG, Chen HJ, Sciacca RR, Rabbani LE. Dynamic Variability of Haemostatic and Fibrinolytic Factors in Young Women. J Clin Endocrinol Metab 2004; 89:6 (179–84). DOI: 10.1210/jc.2004-0598

62. Yildiz S.Y., P. Kuru P., Oner E.T., Agirbasil M. Functional Stability of Plasminogen Activator Inhibitor 1. The Scientific World Journal. 2014; 11 pages. DOI: 10.1155/2014/858293

63. Mehta R., Shapiro A.D. Plasminogen activator inhibitor type 1 deficiency. Review Haemophilia. 2008;14 (6): 1255–60. DOI: 10.1111/j.1365-2516.2008.01834.x

64.